ClinicalTrials.gg

Program

Gabapentin

Also written as “gabapentin”, “gabapentin 600 mg” and “Gabapentin Extended Release tablets”.

Its studies are mostly in Sleep Initiation and Maintenance Disorders · Hot Flashes · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 8 companies.

Furthest: phase 4, since Sep 28, 200744 company-led studies, 1 open or runningNext primary completion: Jan 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris201 open or runningphase 4since Sep 28, 2007Sep 8, 2005Jan 31, 2027phase 4 · NCT07813026
Depomed80 open or runningphase 4since Jun 5, 2017Jun 8, 2006none ahead
Teva Pharmaceutical Industries60 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
Sun Pharmaceutical Industries40 open or runningno phasesince Oct 22, 2008Oct 22, 2008none ahead
GlaxoSmithKline20 open or runningphase 1since Sep 29, 2011Sep 29, 2011none ahead
Pharmaceutical Research Management srl20 open or runningphase 3since Mar 18, 2016Mar 18, 2016none ahead
Nang Kuang Pharmaceutical10 open or runningphase 4since Feb 24, 2014Feb 24, 2014none ahead
Pfizer10 open or runningphase 1since May 5, 2010May 5, 2010none ahead

Also a collaborator on its studies: chiltern-international-inc and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 30 studies since Sep 8, 2005.

  1. Sep 30, 2009Phase 1 study in HealthyViatris · NCT00987779 · 26 enrolled · Singapore
  2. Mar 2, 2010Phase 3 study in Hot FlashesDepomed · NCT01080300 · 600 enrolled · United States
  3. May 5, 2010Pfizer's first study: phase 1 study in HealthyNew to PfizerPfizer · NCT01119222 · 19 enrolled · Belgium
  4. Sep 29, 2011GlaxoSmithKline's first study: phase 1 study in NeuralgiaNew to GlaxoSmithKlineGlaxoSmithKline · NCT01485185 · 48 enrolled · United Kingdom
  5. Nov 28, 2012Phase 1 study in EpilepsyGlaxoSmithKline · NCT01738893 · 26 enrolled
  6. Jun 25, 2013Phase 3 study in Sleep Initiation and Maintenance DisordersViatris · NCT01888497 · 59 enrolled · United States
  7. Feb 24, 2014Nang Kuang Pharmaceutical's first study: phase 4 study in PainNew to Nang Kuang PharmaceuticalNang Kuang Pharmaceutical · NCT02074267 · 40 enrolled · Taiwan
  8. Mar 18, 2016Pharmaceutical Research Management srl's first study: phase 3 study in Chronic PainNew to Pharmaceutical Research Management srlPharmaceutical Research Management srl · NCT02722603 · 2 enrolled · Germany, Netherlands
  9. Jun 5, 2017Phase 4 study in HealthyDepomed · NCT03179345 · 32 enrolled
  10. Aug 30, 2017Phase 2 study in Chronic PainPharmaceutical Research Management srl · NCT03275012
  11. Sep 24, 2020Phase 4 study in Abuse PotentialViatris · NCT04570436 · 52 enrolled · United States
  12. Mar 8, 2022Phase 4 study in Abuse PotentialViatris · NCT05319756 · 54 enrolled · United States
  13. Aug 17, 2026Phase 4 study in Healthy Non-dependent, Recreational Sedative UsersViatris · NCT07777965 · 44 enrolled · United States
  14. Sep 4, 2026Phase 4 study in HealthyViatris · NCT07813026 · 60 planned · United States

Ahead

  1. Jan 31, 2027Primary completion: phase 4 study in HealthyViatris · NCT07813026

TargetBeta

“Voltage-gated calcium channel modulator”ChEMBL 37, by rule

Other programs on the same 26 targets

ProgramCompanyFurthest phaseStudies
PregabalinruleViatrisphase 4149

Studies

All 44 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07813026Healthy · United States4RecruitingViatrisJan 31, 202760
NCT07777965Healthy Non-dependent, Recreational Sedative Users · United States4CompletedViatrisAug 31, 202644
NCT05319756Abuse Potential · United States4CompletedViatrisDec 31, 202154
NCT04570436Abuse Potential · United States4CompletedViatrisNov 10, 202252
NCT03275012Chronic Pain2WithdrawnPharmaceutical Research Management srlOct 21, 20190
NCT03179345Healthy4CompletedDepomedNov 20, 201532
NCT02722603Chronic Pain · Germany, Netherlands3TerminatedPharmaceutical Research Management srlMay 31, 20192
NCT02074267Pain · Taiwan4CompletedNang Kuang PharmaceuticalJun 201140
NCT01888497Sleep Initiation and Maintenance Disorders · United States3CompletedViatrisDec 14, 201359
NCT01738893Epilepsy1CompletedGlaxoSmithKlineJan 22, 201126
NCT01485185Neuralgia · United Kingdom1CompletedGlaxoSmithKlineJul 3, 201248
NCT01119222Healthy · Belgium1CompletedPfizerOct 200819
NCT01080300Hot Flashes · United States3CompletedDepomedSep 2011600
NCT00987779Healthy · Singapore1CompletedViatrisOct 200926
NCT00865631Healthy · United States1CompletedTeva Pharmaceutical IndustriesJun 199918
NCT00865423Healthy · United States1CompletedTeva Pharmaceutical IndustriesFeb 200128
NCT00865059Healthy · United States1CompletedTeva Pharmaceutical IndustriesFeb 200124
NCT00864760Healthy · United States1CompletedTeva Pharmaceutical IndustriesJun 199930
NCT00864305Healthy · United States1CompletedTeva Pharmaceutical IndustriesJan 199818
NCT00864058Healthy · United States1CompletedTeva Pharmaceutical IndustriesJan 199830
NCT00785772Renal Insufficiency · Japan4TerminatedViatrisApr 20101
NCT00778765Healthy · Canada–CompletedSun Pharmaceutical IndustriesOct 200224
NCT00778401Healthy · United States–CompletedSun Pharmaceutical IndustriesOct 200228
NCT00778271Healthy · Canada–CompletedSun Pharmaceutical IndustriesOct 200226
NCT00778232Healthy · United States–CompletedSun Pharmaceutical IndustriesNov 200222
NCT00777023Hot Flashes · United States3CompletedDepomedJul 2009565
NCT00755417Hot Flashes · United States3CompletedDepomedAug 2009541
NCT00712439Pain2CompletedDepomedNov 2006147
NCT00674752Sleep Initiation and Maintenance Disorders · United States3CompletedViatris377
NCT00667108Sleep Initiation and Maintenance Disorders · United States3CompletedViatris784
NCT00666939Sleep Initiation and Maintenance Disorders · United States3CompletedViatris773
NCT00666796Sleep Initiation and Maintenance Disorders · United States4CompletedViatris20
NCT00666770Sleep Initiation and Maintenance Disorders · United States3CompletedViatris309
NCT00666575Sleep Initiation and Maintenance Disorders · United States3CompletedViatris2,105
NCT00659100Sleep Initiation and Maintenance Disorders · United States3CompletedViatris1,254
NCT00644748Diabetic Neuropathies · Brazil4CompletedViatris95
NCT00636636Neuralgia, Postherpetic · United States, Argentina, Russian Federation3CompletedDepomedAug 2009452
NCT00620555Epilepsies, Partial · Japan3CompletedViatrisDec 201065
NCT00603473Epilepsies, Partial · Japan3CompletedViatrisDec 200992
NCT00584779Renal Insufficiency · Japan4TerminatedViatrisDec 20078
NCT00537940Epilepsy · Costa Rica, El Salvador, Guatemala and more4CompletedViatrisJul 2013482
NCT00511953Hot Flashes · United States2CompletedDepomedDec 2007108
NCT00335933Neuralgia, Postherpetic · United States3CompletedDepomed378
NCT00163046Sleep Initiation and Maintenance Disorders · United States3CompletedViatris256

How it is read

Names in the registry

  • “Gabapentin”, 27 entries
  • “gabapentin”, 5 entries
  • “gabapentin 600 mg”, 3 entries
  • “Gabapentin Extended Release tablets”, 3 entries
  • “Gabapentin 800 mg tablets, single dose (1 tablet)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.